SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3557 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3407Distribution of COVID-19 Monoclonal Antibody Therapeutics 1m doses distributed BioBait-11/29/2021
3406BETv1 phase 3 trial updated to "Completed" on ct dot gov, but no resulCuttingEdge Bio-11/22/2021
3405Alnylam R&D day. Featuring some regn collaboration products. App, hsd, c5BioBait111/19/2021
3404A few eu countries having spikes. Germany BioBait-11/12/2021
3403The eu approval. Should drive Roche 2022 sales. Faster than the FDA?BioBait-11/12/2021
3402Regeneron’s COVID antibody drug shows protection for up to 8 months. pheilman_-11/9/2021
3401<The current regen-cov order last to year end. Maybe get one more order to reBioBait-11/5/2021
3400BMY and JNJ are jointly developing an oral inhibitor of Factor XIa that will be DewDiligence_on_SI-11/2/2021
3399A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to BioBait-11/2/2021
3398Roche COV2 535 for Q3 470 for q2 177usd for q1 Dupi 1632 +53%BioBait-11/2/2021
3397FDA approves Roche’s Lucentis-eluting implant for wet AMD: businesswire.comDewDiligence_on_SI-10/22/2021
3396COMPOSITIONS FOR TREATING AND/OR PREVENTING CORONAVIRUS INFECTIONS Second generBioBait-10/21/2021
3395My impression on this is that there must be some compelling scientific reason thCuttingEdge Bio-10/19/2021
3394Agreed, by the time it it gets EUA approval I think the Covid landscape will havFelix B-10/18/2021
3393Looks like swapping out Casirivimab for a different (new) antibody, for a new 2-CuttingEdge Bio-10/18/2021
3392COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+ImdevBioBait-10/18/2021
3391Abrocitinib: investorshub.advfn.comDewDiligence_on_SI-10/15/2021
3390True. This looks like the answer to the question of whether FDA would expand labCuttingEdge Bio-10/12/2021
3389If regn thought COVID was over would it run this large trial. A Study to EvaluBioBait-10/12/2021
3388<Plus discount for eylea coming off patent. I don’t believe it but Analysts dMiljenko Zuanic-10/11/2021
3387I am not too concerned with Eylea going off patent since I believe due it's Felix B-10/6/2021
3386On a good note, but not for 2023. Alnylam/regn CNS programBioBait-10/5/2021
3385Yes, I assume the 1.4 m inventory will be all gone early next year. Then anothBioBait-10/5/2021
3384Not sure if you're aware, but they already got a new re-order, announced lesCuttingEdge Bio110/5/2021
3383This article discuss impact on mRNA stocks. I think it’s different for mABS. BioBait-10/5/2021
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News